E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
castrate-resistant prostate cancer |
|
E.1.1.1 | Medical condition in easily understood language |
castrate-resistant prostate cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10076506 |
E.1.2 | Term | Castration-resistant prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) |
|
E.2.2 | Secondary objectives of the trial |
To assess prostate cancer-specific survival (events including only deaths due to prostate cancer) To assess progression-free survival (including PSA progression by PCWG3 criteria (see appendix 3) (recommended) or if not by investigators assessment) To assess radiographic progression-free survival (progression defined by PCWG3 criteria (recommended)) To determine time to next anticancer treatment To describe the safety (NCI-CTCAE, Version 5.0). G1 to G5 AEs considered related to acetylsalicylic acid and/or statin will be collected in the CRF. Regarding all others AEs only G3-5 have to be collected. To describe cardio-vascular morbidity: cardiovascular hospitalization (e.g. stroke, myocardial infarction) and cardio-vascular mortality or any G3/4 cardiovascular AE To determine the changes from baseline of BMI (BMI=weight (kg)/height (m)2), body weight and waist measure under treatment and correlation with OS
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histologically confirmed adenocarcinoma of the prostate and no curative local therapy considered possible • Age ≥ 18 years, life expectancy of at least 6 months • CRPC defined as tumor progression (PSA increase on at least 2 separate values separated by at least 1 week or progression on imaging) while on Androgen Deprivation Therapy (orchiectomy, LHRH agonist or –antagonist) with documented serum testosterone levels ≤ 1.7 nmol/L (≤ 0.50 ng/mL). Ongoing concurrent use of LHRH agonist or antagonist is required if the patient has not been surgically castrated • Presence (M1) or absence (M0) of metastases on imaging • Performance status 0, 1 or 2 • No previous use of life- prolonging treatments for CRPC (including abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease is allowed. • Adequate renal function within 30 days prior to registration: calculated creatinine clearance ≥ 50 mL/min, according to the formula of Cockcroft-Gault and adequate liver function with levels of AST and ALT ≤ 3xULN and no signs for cholestasis. • Participation in other clinical trials is allowed except for trials with the same primary endpoint, i.e. OS • Patient authorized to participate to a clinical trial by specific country regulation (eg patient affiliated to a social security system or beneficiary of the same) • Information delivered to patient and informed consent form signed by the patient.
|
|
E.4 | Principal exclusion criteria |
• Previous localised malignancy within 2 years with the exception of localized non-melanoma skin cancer and Ta or Tis bladder cancer (patients with asymptomatic Chronic Lymphoïd Leukemia can be included) • Previous metastatic malignancy within 5 years • Patient currently taking daily acetylsalicylic acid or a daily statin within the last 6 months • Patients with active liver disease (hepatitis B or C, cirrhosis) or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal or cholestasis . Patients with excessive alcohol intake or history of a relevant liver disease • Known hypersensitivity or intolerance to acetylsalicylic acid or atorvastatin or hypersensitivity to any of its components • Contra-indication to acetylsalicylic acid or atorvastatin according to label, including known high-risk for haemorrhage, • History of or active myopathy or significantly elevated (> 5 times ULN) CK levels • History of recent stroke or transient ischemic attack (TIA). • Any concomitant drugs contraindicated for use with the trial drugs according to the product information (e.g. Fucidic acid, potent inhibitors of CYP3A4 or transport proteins: ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tripanavir, telaprevir, saquinavir, darunavir, fosamprenavir, boceprivir, gemfibrozil, fenofibrate, etc) • Any serious underlying medical condition (by the investigator’s judgement) which could impair the ability of the patient to participate in the trial • Patients with hereditary galactose intolerance, Lapp-lactase deficiency or Glucose-Galactose-malabsorption • Compliance with trial medical follow-up impossible due to geographic, social or psychological reasons • Psychiatric disorder precluding understanding of information about trial related topics, providing informed consent, or interfering with compliance for oral drug intake |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival (OS). OS will be calculated from the date of randomization to the date of death (or the last follow-up date in case of censored data). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Efficacy: -Prostate cancer- specific-survival (events including only deaths due to prostate cancer) -Progression-free survival (PFS) (including PSA progression by PCWG3 criteria (recommended) or if not, by investigator’s assessment) -Radiographic progression-free survival (progression defined by PCWG3 criteria (recommended) -Time to next anticancer treatment defined as a time from randomization date to the first new anti-cancer treatment -Baseline and Changes of BMI (BMI=weight (kg)/height (m2), body weight and waist measure under treatment Tolerance: Each patient will be regularly assessed for any potential adverse events and disease related signs and symptoms during the whole study treatment and within 30 days following the last dose. -Safety (NCI-CTC AE V5.0). G1 to G5 acetylsalicylic acid and statin-related known AEs will be collected in the CRF and regarding all the others events only G3-5 should be collected too. -Cardio-vascular morbidity: cardiovascular hospitalization (e.g. stroke, myocardial infarction) and Cardio-vascular mortality or any G3/4 cardiovascular AE
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 31 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 114 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Denmark |
Finland |
Germany |
Ireland |
Italy |
Spain |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Death of the last patient (the primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS)) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 19 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 19 |